Italian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

polysaccharide/cefalea

Il collegamento viene salvato negli appunti
Pagina 1 a partire dal 49 risultati

Use of Typhoid Vi-Polysaccharide Vaccine as a Vaccine Probe to Delineate Clinical Criteria for Typhoid Fever

Solo gli utenti registrati possono tradurre articoli
Entra registrati
Blood cultures (BCs) detect an estimated 50% of typhoid fever cases. There is need for validated clinical criteria to define cases that are BC negative, both to help direct empiric antibiotic treatment and to better evaluate the magnitude of protection conferred by typhoid vaccines. To derive and
BACKGROUND The current study evaluated the reactogenicity and immunogenicity of Typherix, a new typhoid Vi polysaccharide vaccine, in children aged between 4 and 14 years. METHODS This phase III, open, single-group study was conducted at a single centre in South Africa. Healthy children aged between

Reactogenicity and immunogenicity of a single dose of a typhoid Vi polysaccharide vaccine in adolescents.

Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND The current study evaluated the reactogenicity and immunogenicity of Typherix, a recently developed Vi polysaccharide typhoid vaccine, in adolescents. METHODS This phase II, open, single-group study was conducted at a single centre in South Africa. Healthy adolescents, aged between 11 and
A clinical trial was conducted to compare intramuscular (im) with subcutaneous (sc) routes for administration of quadrivalent meningococcal polysaccharide vaccine in 141 adults. Safety assessment showed the im route had reduced erythema (P<.01) and reduced headache on days 1 and 2 (P<.05).
Extensive use of meningococcal AC polysaccharide (MACP) vaccines has raised concerns about induction of immunologic hyporesponsiveness to C polysaccharide. We investigated the immunogenicity and safety of a meningococcal C-tetanus conjugate (MCC-TT) vaccine in naive adults and prior MACP vaccinees.
OBJECTIVE To evaluate the safety of meningococcal group AC bivalent polysaccharide conjugate vaccine among children aged 5-24 months old. METHODS From July 2011 to June 2012, a total of 34 411 children aged 5-24 month-old who voluntarily vaccinated meningococcal group AC bivalent polysaccharide

Safety data on meningococcal polysaccharide vaccine from the Vaccine Adverse Event Reporting System.

Solo gli utenti registrati possono tradurre articoli
Entra registrati
Recent recommendations by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices may lead to the increased use of the meningococcal polysaccharide vaccine. The Vaccine Adverse Event Reporting System (VAERS) is useful for the detection of previously unrecognized

Inhalative vaccination with pneumococcal polysaccharide in patients with chronic obstructive pulmonary disease.

Solo gli utenti registrati possono tradurre articoli
Entra registrati
In order to determine the feasibility of inhalative vaccination with polysaccharide antigen in patients with chronic obstructive pulmonary disease (COPD), we used controlled inhalation of a defined dose of Pneumovax in a randomized 3-arm study. The vaccine was either deposited in the alveoli
In this study, we compared the immunogenicities of two lots of meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) that differed in serogroup A polysaccharide (PS) O-acetylation levels and evaluated their immunogenicities and safety in comparison to a licensed ACWY polysaccharide
BACKGROUND Older adults are at highest risk of invasive pneumococcal disease (IPD) and are recommended to receive vaccination with 23-valent pneumococcal polysaccharide vaccine (PPV23). Antibody concentrations decline following vaccination. We evaluated the immunogenicity and reactogenicity of

Clinical effect of a polysaccharide-rich extract of Acanthopanax senticosus on alcohol hangover.

Solo gli utenti registrati possono tradurre articoli
Entra registrati
The present study aimed to examine the effects polysaccharide-rich extract of Acanthopanax senticosus (PEA) on blood alcohol concentration (BAC) and hangover as well as blood lab parameters. A randomized, placebo-controlled, double-blind crossover trial was conducted. The PEA was orally administered

Annual report: surveillance of adverse events following immunisation in Australia, 2009.

Solo gli utenti registrati possono tradurre articoli
Entra registrati
This report summarises Australian passive surveillance data for adverse events following immunisation (AEFI) reported to the Therapeutic Goods Administration (TGA) for 2009, and describes reporting trends over the 10-year period 2000 to 2009. There were 2,396 AEFI records for vaccines administered

Ethnopharmacological Investigations of Phytochemical Constituents Isolated from the Genus Cuscuta.

Solo gli utenti registrati possono tradurre articoli
Entra registrati
The genus Cuscuta, of the family Cuscutaceae, is present in plants and has been traditionally used medicinally against many diseases and conditions, notably depression, mental illness, headache, spleen disease, jaundice, diabetes mellitus, and hypertension. Large numbers of phytochemical

Annual report: surveillance of adverse events following immunisation in Australia, 2008.

Solo gli utenti registrati possono tradurre articoli
Entra registrati
This report summarises Australian passive surveillance data for adverse events following immunisation (AEFI) reported to the Therapeutic Goods Administration (TGA) for 2008, and describes reporting trends over the 9-year period 2000 to 2008. There were 1,542 AEFI records for vaccines administered in
In a randomized, placebo-controlled, monocenter, observer blinded study conducted in an area where dengue is endemic, we assessed the safety and immunogenicity of a recombinant, live, attenuated, tetravalent dengue vaccine candidate (CYD-TDV) in 2-11 year-olds with varying levels of pre-existing
Unisciti alla nostra
pagina facebook

Il database di erbe medicinali più completo supportato dalla scienza

  • Funziona in 55 lingue
  • Cure a base di erbe sostenute dalla scienza
  • Riconoscimento delle erbe per immagine
  • Mappa GPS interattiva - tagga le erbe sul luogo (disponibile a breve)
  • Leggi le pubblicazioni scientifiche relative alla tua ricerca
  • Cerca le erbe medicinali in base ai loro effetti
  • Organizza i tuoi interessi e tieniti aggiornato sulle notizie di ricerca, sperimentazioni cliniche e brevetti

Digita un sintomo o una malattia e leggi le erbe che potrebbero aiutare, digita un'erba e osserva le malattie ei sintomi contro cui è usata.
* Tutte le informazioni si basano su ricerche scientifiche pubblicate

Google Play badgeApp Store badge